TL;DR
This study validates the new 5-level EuroQol (EQ-5D-5L) questionnaire for assessing the quality of life in adults with asthma. The EQ-5D-5L demonstrated good reliability and construct validity, showing it can effectively differentiate between groups with varying asthma control and chronic conditions, making it a promising tool for eHealth programs monitoring asthma patients.
What Problem Does This Paper Address?
The EuroQol Group's original EQ-5D questionnaire, a widely used tool for measuring health-related quality of life (HRQoL), has a known limitation: a "ceiling effect." This means that a significant portion of patients, especially those with milder conditions, report the best possible health state, making it difficult to detect subtle improvements or differences in HRQoL. To address this, the EQ-5D-5L was developed with more response options (5 levels instead of 3) to increase its sensitivity. While the EQ-5D-5L has been tested in other patient groups, its metric properties, specifically its validity and reliability in assessing HRQoL in adults with asthma, had not yet been evaluated. This study aims to fill that gap.
Methods
The researchers conducted a cross-sectional study involving adults aged 18-40 with persistent asthma, recruited from primary care settings in France and England. Participants self-completed the EQ-5D-5L questionnaire online. To calculate the EQ-5D index, they used two different preference value sets: the English preference value set for the EQ-5D-5L and a French 3L-5L crosswalk value set.
The study evaluated several aspects of the EQ-5D-5L:
- Distribution: They examined response patterns across the EQ-5D-5L dimensions and calculated the EQ-5D index distribution, including ceiling and floor effects.
- Construct Validity: This was assessed by comparing EQ-5D-5L scores between groups of patients hypothesized to differ in their HRQoL. These "known groups" were defined by factors like the number of chronic conditions, the number of short-acting beta-agonist (SABA) canisters prescribed in the past year, SABA use in the last 4 weeks, and asthma control levels (measured by the Asthma Control Questionnaire - ACQ).
- Reliability: Internal consistency was measured using Cronbach's alpha.
Datasets
The study utilized data from the ASTRO-LAB cohort, a prospective longitudinal study of asthmatic patients. The primary dataset for this analysis consisted of baseline data from 312 patients who completed the Web-based survey, with 279 ultimately included in the final analysis after exclusions. No new benchmarks were introduced; the study focused on evaluating an existing instrument.
Key Insights and Ideas
- Improved Sensitivity: The EQ-5D-5L appears to be more sensitive than its predecessor (EQ-5D-3L) in the asthma population, as evidenced by a lower ceiling effect compared to previous studies. This suggests it can better capture the nuances of HRQoL in this group.
- Web-Based Feasibility: The high completion rate of the EQ-5D-5L via a Web-based survey (93%) indicates that this administration method is feasible and well-accepted by asthma patients, supporting its use in eHealth programs.
- Value Set Comparison: The study found that using either the English EQ-5D-5L value set or the French 3L-5L crosswalk value set yielded similar results for the EQ-5D-5L index, suggesting the crosswalk is a reasonable interim solution until a definitive French EQ-5D-5L value set is available.
- Discriminatory Power: The EQ-5D-5L effectively distinguished between groups with different levels of asthma control and varying numbers of chronic conditions, a key indicator of its construct validity.
Key Results
- Ceiling Effect: The ceiling effect for the EQ-5D-5L was 26.5% (74/279), which is lower than ceiling effects reported for the EQ-5D-3L in previous asthma studies (e.g., 59% and 50%). The floor effect was null.
- EQ-5D-5L Index: The mean EQ-5D-5L index was 0.88 (SD 0.14) using the English value set and 0.83 (SD 0.19) using the French 3L-5L crosswalk value set.
- Construct Validity: Large effect sizes were observed for groups defined by asthma control (ACQ scores), with effect sizes of 1.06 and 1.04 between well-controlled and not well-controlled asthma groups. Moderate effect sizes (around 0.5) were found for groups defined by chronic conditions and SABA use.
- Reliability: Cronbach's alpha was 0.69, which is considered acceptable for internal consistency.
- Web-Based Participation: 53.7% of the initial cohort completed the Web-based survey, and 92.9% of those who started the survey completed the EQ-5D-5L.
Limitations and Future Work
The authors acknowledge several limitations:
- Direct Comparison: A direct comparison with the EQ-5D-3L was not possible due to differences in study populations and designs. While the EQ-5D-5L showed better properties, these differences might not be solely attributable to the instrument itself.
- No Asthma-Specific Measure: The study did not include an asthma-specific HRQoL measure, preventing a direct comparison of the EQ-5D-5L's performance against such instruments.
- Web-Based Only: All patients completed the EQ-5D-5L online, so the usability of this mode compared to others (e.g., telephone) could not be assessed.
- Generalizability: The study focused on mild-to-moderate persistent asthma patients aged 18-40. Results may not generalize to patients with intermittent or severe persistent asthma, or those older than 40.
- Non-response Bias: While demographic and clinical characteristics were similar between respondents and non-respondents, potential differences in unmeasured psychological traits could exist.
Future work should focus on evaluating the responsiveness of the EQ-5D-5L over time in asthma patients and conducting head-to-head comparisons with disease-specific instruments to assess sensitivity to change.
Summary updated